The CMPK2 Knockout Raji Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal population of Raji B lymphoblastoid cells harboring targeted disruption of the CMPK2 gene. This knockout model provides a versatile platform for investigating cytidine/uridine monophosphate kinase 2 function in pyrimidine nucleotide metabolism. The polyclonal nature avoids clonal artifacts and reflects a broad spectrum of editing events, enabling robust phenotypic analysis in a Burkitt??s lymphoma background.
Raji cells, derived from an EBV-positive Burkitt??s lymphoma patient, represent a classic B-cell malignancy model characterized by rapid proliferation and expression of viral oncoproteins. These lymphoblastoid cells are extensively used to study lymphomagenesis, viral latency, and metabolic adaptations in cancer. Their EBV positivity adds a dimension for probing host-virus interactions that may influence nucleotide metabolism and therapeutic responses.
CMPK2 encodes a mitochondrial pyrimidine nucleotide kinase catalyzing phosphate transfer from ATP to UMP and CMP, producing UDP and CDP, and similarly phosphorylates dUMP and dCMP. This enzyme functions within the nucleotide salvage pathway, supplying precursors for nucleic acid synthesis. CMPK2 expression is transcriptionally regulated by E2F factors and c-Myc, and its activity is modulated by PI3K/AKT and mTORC1 signaling. Downstream, the nucleotide products serve as substrates for RNA and DNA polymerases. Disruption of CMPK2 perturbs nucleotide pool homeostasis, potentially affecting DNA replication and cell cycle progression.
In the context of Raji lymphoma cells, loss of CMPK2-mediated pyrimidine phosphorylation may intensify reliance on de novo nucleotide synthesis or render cells vulnerable to metabolic stress. This model enables dissection of how lymphoma metabolism interfaces with oncogenic signaling, particularly via c-Myc-driven biosynthetic demands. Additionally, EBV-encoded factors may modulate the salvage pathway, and CMPK2 knockout could uncover synthetic lethal interactions exploitable in lymphoproliferative disorders.
Researchers can employ this polyclonal knockout product in diverse assays, including Western blotting and RT-qPCR to validate CMPK2 disruption, cell viability (MTT) and proliferation assays to assess growth phenotypes, and apoptosis and cell cycle analysis by flow cytometry. Nucleotide pool profiling via LC-MS can quantify metabolic shifts, while drug sensitivity tests with pyrimidine antimetabolites (e.g., gemcitabine) enable screening for therapeutic vulnerabilities. These applications support studies in B-cell lymphoma biology, nucleotide kinase function, EBV-host interactions, and the development of nucleotide-depleting treatments. For further information, please contact Ascent Research.
